ThromboGenics NV: Business Update ( LEUVEN Belgium May 14 /- -...)

ThromboGenics NV: Business Update

Date:5/14/2009

LEUVEN, Belgium, May 14 /PRNewswire-FirstCall/ --

- Regulated Information

- Disclosure in Accordance With the Law of May 2, 2007

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update for the three month period ending 31 March, 2009.

Patrik De Haes, CEO of ThromboGenics, commenting on today's announcement, said: "ThromboGenics has had an excellent start to 2009 as we continue to build on the significant progress made in 2008. Patient recruitment in the Phase III development program of our lead product microplasmin for back of the eye disease is on track, and we believe that this exciting product will allow us to build our own ophthalmology franchise over time. We have also continued to make considerable progress with our other key clinical and pre-clinical programs. We have begun a Phase II trial for our novel long-acting anticoagulant TB-402 and also received the first milestone from our strategic agreement with Roche for the novel anti-cancer agent TB-403. The development of Anti-VPAC, our pre-clinical candidate for the treatment of thrombocytopenia, received a major boost when we were awarded a EUR3.2 million grant from the IWT.

"I am confident that ThromboGenics will continue to generate significant shareholder value throughout the remainder of 2009 as we continue to maximize the value of our exciting product pipeline."

Financial Update

- ThromboGenics achieved revenues of EUR3.3 million in 1st
Quarter 2009. Most of this income came from the EUR3 million technology
transfer success fee from Roche received under the terms of the
strategic alliance for the novel anti-cancer antibody, TB-403.
Operating expenses were EUR4.3 million during this three month period,

GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody

Post Your Comments:

ThromboGenics NV: Business Update( LEUVEN Belgium May 14 /- -...)